Grupo Casa Saba Reports Modest Growth

February 2008 | Company News Alert

Grupo Casa Saba (GCS)'s uninspiring Q407 results have underlined BMI's warning that the domestic distribution giant must look to international expansion or for a foreign tie up if it is to increase turnover. Fourth quarter sales grew by 3.85% compared with Q406 to reach US$7.1bn, while profits reached US$383.9mn. Sales in GCS's private pharmaceutical division, which accounts for over 80% of revenue, grew by just 3.66%. When compared with overall pharmaceutical market growth, which BMI estimates to have been 9% in 2007, these results look doubly

If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.